FAQ and methodology
All companies on the list must publish financial data and report part or all of their figures to a government agency. In the U.S., private companies and cooperatives...
More
2011
2010
2009
2008
2007
2006
2005
Switch industry
1 Johnson & Johnson 107 61,095 15 10,576 -4 2 Pfizer 143 48,418 -8 8,144 -58 3 GlaxoSmithKline 151 45,447 6 10,432 5 4 Roche Group 175 40,315 16 8,135 29 5 Sanofi-Aventis 178 39,977 8 7,204 43 6 Novartis 181 39,800 8 11,946 67 7 AstraZeneca 265 29,559 12 5,595 -7 8 Abbott Laboratories 312 25,914 15 3,606 110 9 Merck 332 24,198 7 3,275 -26 10 Wyeth 381 22,400 10 4,616 10 11 Bristol-Myers Squibb 427 19,977 12 2,165 37 12 Eli Lilly 453 18,634 19 2,953 11
1 Johnson & Johnson 61,095 80,954 2 Pfizer 48,418 115,268 3 GlaxoSmithKline 45,447 61,714 4 Roche Group 40,315 69,058 5 Sanofi-Aventis 39,977 105,143 6 Novartis 39,800 75,452 7 AstraZeneca 29,559 47,957 8 Abbott Laboratories 25,914 39,714 9 Merck 24,198 48,351 10 Wyeth 22,400 42,717 11 Bristol-Myers Squibb 19,977 26,172 12 Eli Lilly 18,634 26,788
From the July 21, 2008 issue